Galapagos NV

Galapagos NV is a biotechnology company focused on the discovery and development of small molecule medicines. Its core business model involves preclinical drug discovery and development, a process that inherently requires animal testing for regulatory compliance and safety assessment. The company’s SEC filings explicitly list “completion of preclinical laboratory tests, animal studies and formulation studies” as part of its development process for product candidates.

Published research on Galapagos compounds, such as GLPG1972 and GLPG1205, details that “all animal experiments described in the paper were performed according to ethical guidelines approved by the Animal Institutional Care and Use” committees. While the company states it is “actively engaged to refine, reduce and replace (3Rs) testing involving the use of animals,” its business remains fundamentally dependent on animal data to advance drug candidates through regulatory pathways and into clinical trials.